Navigation Links
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Date:4/7/2009

(orgasm with reduced semen), an expected effect of selective alpha blockers. Rates of discontinuing therapy due to retrograde ejaculation were low. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher among RAPAFLO(TM) than placebo-treated patients.

Previously presented data included information that in clinical trials RAPAFLO(TM) was administered with a single dose of medications for erectile dysfunction in healthy male subjects (N=24) and that there were no reported events of symptomatic orthostatis or dizziness.

RAPAFLO(TM) was originally developed by Kissei Pharmaceutical Co., Ltd. in Japan, where RAPAFLO(TM) is the BPH market leader, and licensed to Watson for the US, Canada and Mexico markets.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).

In the U.S., the Watson Brand portfolio includes RAPAFLO(TM), GELNIQUE, TRELSTAR(R) LA, TRELSTAR(R) Depot, Ferrlecit(R), INFeD(R), and Oxytrol(R). In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; Tri-Luma(R) Cream, with Galderma Laboratories; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R) for the treatment of advanced prostate cancer, which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel oral contraceptive.

For press releases and other company information, visit the Watson Web site at http://www.watson.
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
2. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
3. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
4. Watson Launches Generic Biaxin(R) XL
5. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
6. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
7. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
8. Schering-Plough Announces Results of the Early ACS Trial
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
11. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... studies of immunosuppression in kidney transplant ... Aug. 28 "Cylex, Inc., in association,with our Korean ... to,announce our support for a major, multi-center trial of ... medical institutions,in the Republic of Korea," stated Brad Stewart, ...
... - Results Further Support the Clinical Profile of ... Survival of Patients,With Hormone Refractory Prostate Cancer (HRPC), ... therapeutics company,today announced that the primary objective of ... The study showed that even single doses of,Alpharadin ...
Cached Medicine Technology:Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 2Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4
(Date:12/19/2014)... December 19, 2014 The Hermitage ... club in Southern Vermont’s Deerfield Valley, announced today that ... by classic rock songs. , Three time Grammy ... a private concert followed by a trail naming ceremony. ... trail names include: “I’m Alright” the theme song for ...
(Date:12/19/2014)... A new study suggests a possible link between certain ... night sweats -- and higher rates of hip fractures ... menopause, affecting about 60 percent of women. The hormonal ... they then face a higher risk of weakened bones ... moderate or severe menopausal symptoms are more likely to ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... high levels of air pollution late in pregnancy may have ... Researchers found that of nearly 1,800 U.S. women who ... most air pollution during pregnancy were twice as likely to ... the third trimester, specifically, showed the strongest correlation to autism ...
(Date:12/19/2014)... News) -- Traveling through the same U.S. airport gate, ... others within a four-hour time span, illustrating just how ... "The exposures in this report were not prolonged ... terminal, highlighting the fact that measles is highly contagious," ... disease specialist at the U.S. Centers for Disease Control ...
(Date:12/19/2014)... Reinberg HealthDay Reporter THURSDAY, ... on one leg for at least 20 seconds you may ... Difficulty standing on one leg may indicate that small strokes ... for more serious strokes is high, the investigators reported online ... showing instability while standing on one leg, as well as ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2
... Jerry A. Boriskin of University of the Rockies Delivers ... when many military men and women are returning home ... member of the University of the Rockies and author ... to recognize and prevent post traumatic stress disorder (PTSD) ...
... Calif., Feb. 20 CUREXO Technology Corporation, pioneer ... robotic products for orthopaedic applications, which is focused ... it has submitted a premarket notification 510(k) application ... for market clearance in the U.S. for use ...
... Executive to Head Company,s Network of International Subsidiaries and ... (Nasdaq: CYNO ), a leading developer and ... systems, today announced the appointment of William T. Kelley ... will be responsible for the company,s direct subsidiaries in ...
... apt to die early, study finds, , , WEDNESDAY, Feb. 25 ... risk of premature death in adulthood as much as smoking ... , Dr. Martin Neovius of the Karolinska Institute and ... military conscription tests in which their body mass index (BMI) ...
... re-alignment of shared services, including Business Technology, ... Device Governance CommitteesROCKVILLE, Md. and PRINCETON, N.J., ... (OAPI) and Otsuka Pharmaceutical Development & Commercialization, ... part of the North American pharmaceutical organizations, ...
... CROSSFIT TRAINER ANDY PETRANEK TO TACKLE THE HOTTEST TREND ... medalist to the growing list of female athletes who ... is part of a burgeoning movement of professional female ... grueling, high-intensity workouts used to train the warrior actors ...
Cached Medicine News:Health News:Leading Cause of Stress to Military War Veterans Key Topic at 35th Advanced International Winter Symposium 2Health News:Leading Cause of Stress to Military War Veterans Key Topic at 35th Advanced International Winter Symposium 3Health News:CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 3Health News:Obesity Just as Risky for Teens as Heavy Smoking 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 3Health News:CrossFit: A Workout Fit for an Olympian 2
... Cochrane Reviews enable all those involved with ... with the very latest evidence in their ... becomes harder each year as the volume ... problem by delivering the best single source ...
Over 10,000 entries. This dictionary is both a home medical guide and as an aid for all those working in the medical and allied professions. The entries are laid out and jargon-free....
... for PDA is a combination of the Medical ... Dictionary pocket for PDA. The first part of ... overview of the Spanish language, i.e. pronunciation, common ... of anatomy and medical terminology. The second part ...
Taber's Cyclopedic Medical Dictionary is published by F.A. Davis. Contains approximately 56,000 terms....
Medicine Products: